Market Closed -
Nasdaq
04:00:00 2024-05-10 pm EDT
|
5-day change
|
1st Jan Change
|
0.9
USD
|
+0.08%
|
|
-8.16%
|
-15.89%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
149.4
|
88.18
|
36.94
|
31.23
|
-
|
-
|
Enterprise Value (EV)
1 |
149.4
|
88.18
|
36.94
|
31.23
|
31.23
|
31.23
|
P/E ratio
|
-
|
-3.14
x
|
-1.65
x
|
-1.75
x
|
-1.36
x
|
-1.32
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
7.57
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
7.57
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-11.4
x
|
-
|
-
|
-1.25
x
|
-0.69
x
|
-0.61
x
|
FCF Yield
|
-8.75%
|
-
|
-
|
-80%
|
-145%
|
-163%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
33,504
|
33,786
|
34,520
|
34,704
|
-
|
-
|
Reference price
2 |
4.460
|
2.610
|
1.070
|
0.9000
|
0.9000
|
0.9000
|
Announcement Date
|
3/18/22
|
3/21/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
4.124
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-28.36
|
-30.95
|
-22.92
|
-22.02
|
-31.96
|
-39.85
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-966.28%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-
|
-22.46
|
-19.06
|
-28.18
|
-28.53
|
Net income
1 |
-16.24
|
-
|
-27.99
|
-22.46
|
-19.06
|
-36.39
|
-40.23
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-975.5%
|
EPS
2 |
-1.870
|
-
|
-0.8300
|
-0.6500
|
-0.5150
|
-0.6633
|
-0.6800
|
Free Cash Flow
1 |
-
|
-13.08
|
-
|
-
|
-25
|
-45.24
|
-50.9
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,234.35%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
9/14/21
|
3/18/22
|
3/21/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-13.38
|
-6.362
|
-7.374
|
-7.698
|
-7.987
|
-7.889
|
-5.854
|
-6.343
|
-5.223
|
-5.5
|
-5.404
|
-5.075
|
-5.593
|
-5.947
|
-6.771
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-5.686
|
-6.197
|
-5.116
|
-5.459
|
-5.066
|
-4.271
|
-4.748
|
-4.979
|
-6.73
|
Net income
1 |
-
|
-
|
-
|
-
|
-
|
-7.769
|
-5.686
|
-6.197
|
-5.116
|
-5.459
|
-5.066
|
-4.271
|
-4.748
|
-4.979
|
-6.797
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-
|
-
|
-
|
-
|
-
|
-0.2300
|
-0.1700
|
-0.1800
|
-0.1500
|
-0.1500
|
-0.1450
|
-0.1200
|
-0.1300
|
-0.1300
|
-0.1400
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/29/21
|
3/18/22
|
5/13/22
|
8/9/22
|
11/3/22
|
3/21/23
|
5/11/23
|
8/10/23
|
11/9/23
|
3/21/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-13.1
|
-
|
-
|
-25
|
-45.2
|
-50.9
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.25
|
-
|
-
|
-
|
1
|
1.06
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
25.75%
|
Announcement Date
|
9/14/21
|
3/18/22
|
3/21/23
|
3/21/24
|
-
|
-
|
-
|
Average target price
8
USD Spread / Average Target +788.89% Consensus |
1st Jan change
|
Capi.
|
---|
| -15.89% | 31.23M | | +17.96% | 44.96B | | +1.17% | 42.65B | | +48.77% | 41.85B | | -4.27% | 29.04B | | +11.42% | 26.08B | | -21.39% | 19.03B | | +4.86% | 12.75B | | +27.29% | 12.06B | | -3.50% | 11.75B |
Other Biotechnology & Medical Research
|